A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/21/2002	CA2447548A1 Complexes for transferring substances of interest into a cell
11/21/2002	CA2447518A1 Therapeutic use of rank antagonists
11/21/2002	CA2447444A1 Antisense permeation enhancers
11/21/2002	CA2447408A1 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
11/21/2002	CA2447395A1 Targeted delivery of drugs for the treatment of parasitic infections
11/21/2002	CA2447343A1 Method to induce neovascular formation and tissue regeneration
11/21/2002	CA2447314A1 Arginine derivatives
11/21/2002	CA2447305A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002	CA2447286A1 Random gene unidirectional antisense library
11/21/2002	CA2447275A1 Therapeutic delivery of carbon monoxide
11/21/2002	CA2447184A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	CA2447084A1 Benzamidoacetonitriles and their use as antiparasitics
11/21/2002	CA2447052A1 Combined approach to treatment of cancer using a c-myc antisense oligomer
11/21/2002	CA2447050A1 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
11/21/2002	CA2447005A1 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
11/21/2002	CA2447004A1 Antisense modulation of ptp1b expression
11/21/2002	CA2446991A1 Agents that regulate apoptosis
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	CA2446980A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	CA2446957A1 Compaction process for manufacture of sodium phenytoin dosage form
11/21/2002	CA2446956A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2446849A1 Treatment of conditions relating to hormone deficiencies by administration of progestins
11/21/2002	CA2446797A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	CA2446763A1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
11/21/2002	CA2446751A1 Kavalactone compositions and methods of use
11/21/2002	CA2446747A1 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446736A1 Chemoprotection using amifostine and related compounds
11/21/2002	CA2446717A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	CA2446641A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	CA2446605A1 Novel processes for the preparation of adenosine compounds and intermediates thereto
11/21/2002	CA2446593A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2446582A1 Reagents and methods for modulating dkk-mediated interactions
11/21/2002	CA2446113A1 Methods for inactivating viruses
11/21/2002	CA2446106A1 System for delivering cosmetics and pharmaceuticals
11/21/2002	CA2445922A1 Estrogen receptor modulators
11/21/2002	CA2445606A1 Taste masking pharmaceutical composition
11/21/2002	CA2445477A1 Antitumor agents
11/21/2002	CA2445003A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	CA2444627A1 Method for treating ocular hypertension and glaucoma
11/21/2002	CA2443964A1 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	CA2443721A1 Sulfonamide derivatives
11/21/2002	CA2443191A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	CA2443160A1 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
11/20/2002	WO2001091755A1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
11/20/2002	EP1258492A1 N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases
11/20/2002	EP1258491A1 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
11/20/2002	EP1258490A1 Process for preparing indolopyrrolocarbazole derivatives, intermediates therefor, and preparation process of the intermediates
11/20/2002	EP1258481A1 Enaminotriazines as UV filters
11/20/2002	EP1258478A1 Process for producing quinolonecarboxylic acids and intermediates thereof
11/20/2002	EP1258476A1 Alpha-amino acid derivatives, method for their preparation and their use as dipeptidyl-peptidase IV inhibitors (DPP IV)
11/20/2002	EP1258474A2 Alkylamide compounds
11/20/2002	EP1258471A2 Inorganic ion receptor-active compounds
11/20/2002	EP1258255A1 Conjugates of an antibody to CD44 and a maytansinoid
11/20/2002	EP1258254A1 Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
11/20/2002	EP1258253A1 Novel remedies with the use of beta3 agonist
11/20/2002	EP1258252A1 Integrin expression inhibitors
11/20/2002	EP1258250A1 Nerve protective drugs
11/20/2002	EP1258249A1 Oral preparations for diabetes
11/20/2002	EP1258248A2 Tumor treatments comprising a fumagillol derivative and a further antineoplastic agent
11/20/2002	EP1258247A1 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
11/20/2002	EP1258246A2 Controlled release oxycodone compositions
11/20/2002	EP1258245A2 Accelerated release composition containing bromocriptine
11/20/2002	EP1258244A1 High affinity ligands for nociceptin receptor ORL-1
11/20/2002	EP1258243A1 Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
11/20/2002	EP1258200A2 Use of hydroxyflavones for masking of bitterness, and food and pharmaceutical compositions comprising an effective amount thereof
11/20/2002	EP1257669A1 Antisense modulation of e2f transcription factor 3 expression
11/20/2002	EP1257657A2 Autoregulatory expression vector for gene therapy
11/20/2002	EP1257653A2 Phosphodiesterase type 7b
11/20/2002	EP1257642A1 Partners of ptb1 domain of fe65, preparation and uses
11/20/2002	EP1257639A2 Nucleozymes with endonuclease activity
11/20/2002	EP1257565A1 Mucin-1 derived antigens and their use in immunotherapy
11/20/2002	EP1257563A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
11/20/2002	EP1257558A1 Methods for synthesis of alpha-d-gal (1- 3) gal-containing oligosaccharides
11/20/2002	EP1257556A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
11/20/2002	EP1257555A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
11/20/2002	EP1257554A1 Benzoxathiepino[3,4-b]pyridine derivatives, process for their preparation and their use as medicaments
11/20/2002	EP1257553A1 Pyrrolopyrimidinone derivatives, process of preparation and use
11/20/2002	EP1257552A1 Xanthine derivatives, intermediates and use for treating osteoporosis
11/20/2002	EP1257550A1 Platelet adp receptor inhibitors
11/20/2002	EP1257548A1 Benzofuran carboxamides and their therapeutic use
11/20/2002	EP1257547A1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
11/20/2002	EP1257546A1 Kinase inhibitors
11/20/2002	EP1257544A2 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage
11/20/2002	EP1257543A1 Pyridinylimidazoles
11/20/2002	EP1257541A2 Polypharmacophoric agents
11/20/2002	EP1257539A2 Amino pyrazole derivatives useful for the treatment of obesity and other disorders
11/20/2002	EP1257537A1 Therapeutic morpholino-substituted compounds
11/20/2002	EP1257536A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/20/2002	EP1257535A1 Substituted pyridine compounds useful for controlling chemical synaptic transmission
11/20/2002	EP1257530A1 Aminosulfonylbiphenyl derivatives
11/20/2002	EP1257528A1 Aminoalcohol derivatives
11/20/2002	EP1257527A1 (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands
11/20/2002	EP1257526A1 Aniline-derived ligands for the thyroid receptor
11/20/2002	EP1257298A1 Cosmid dna constructs and methods of making and using the same
11/20/2002	EP1257296A2 Caspase activated prodrugs therapy
11/20/2002	EP1257292A1 Use of il-18 inhibitors
11/20/2002	EP1257291A1 Novel antibody with specificity for colon cancer

1 ... 5645 5646 5647 5648 5649 5650 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 ... 7860